Alliance Wealth Advisors LLC UT Boosts Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Alliance Wealth Advisors LLC UT raised its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 6.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 11,529 shares of the company’s stock after buying an additional 672 shares during the period. Alliance Wealth Advisors LLC UT’s holdings in Prestige Consumer Healthcare were worth $900,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC boosted its holdings in Prestige Consumer Healthcare by 19.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,575,170 shares of the company’s stock valued at $113,570,000 after acquiring an additional 255,045 shares during the last quarter. Geode Capital Management LLC grew its stake in Prestige Consumer Healthcare by 4.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock valued at $95,678,000 after purchasing an additional 50,961 shares in the last quarter. Congress Asset Management Co. increased its stake in shares of Prestige Consumer Healthcare by 7.8% in the third quarter. Congress Asset Management Co. now owns 865,123 shares of the company’s stock worth $62,375,000 after buying an additional 62,411 shares during the last quarter. Boston Trust Walden Corp lifted its position in shares of Prestige Consumer Healthcare by 43.5% during the fourth quarter. Boston Trust Walden Corp now owns 831,627 shares of the company’s stock worth $64,942,000 after purchasing an additional 252,089 shares during the last quarter. Finally, Eagle Asset Management Inc. grew its position in shares of Prestige Consumer Healthcare by 0.7% in the 3rd quarter. Eagle Asset Management Inc. now owns 434,514 shares of the company’s stock worth $31,328,000 after acquiring an additional 3,227 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Wall Street Analyst Weigh In

PBH has been the topic of several research reports. StockNews.com upgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Friday, January 24th. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective for the company. in a report on Monday, December 9th. Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Finally, DA Davidson restated a “buy” rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $85.25.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE PBH opened at $75.35 on Tuesday. The firm has a market cap of $3.72 billion, a price-to-earnings ratio of 18.33, a P/E/G ratio of 2.15 and a beta of 0.50. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. The business’s 50-day simple moving average is $79.63 and its 200-day simple moving average is $75.19. Prestige Consumer Healthcare Inc. has a 52 week low of $60.00 and a 52 week high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The firm had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. During the same period in the prior year, the firm earned $1.07 EPS. The business’s revenue was down .9% on a year-over-year basis. As a group, equities research analysts expect that Prestige Consumer Healthcare Inc. will post 4.46 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 9,885 shares of the business’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $81.97, for a total value of $810,273.45. Following the completion of the transaction, the senior vice president now directly owns 18,835 shares of the company’s stock, valued at approximately $1,543,904.95. The trade was a 34.42 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Adel Mekhail sold 9,063 shares of the company’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total value of $743,166.00. Following the transaction, the executive vice president now directly owns 18,365 shares in the company, valued at $1,505,930. This trade represents a 33.04 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,810 shares of company stock worth $3,187,300 over the last three months. 1.60% of the stock is currently owned by corporate insiders.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.